Indication
Spinal Muscular Atrophy Type 2
3 clinical trials
4 products
Product
OAV101Clinical trial
A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Type 2 Spinal Muscular Atrophy (SMA) Patients Who Are ≥ 2 to < 18 Years of Age, Treatment Naive, Sitting, and Never AmbulatoryStatus: Active (not recruiting), Estimated PCD: 2024-12-02
Clinical trial
Phase 2 Active Treatment Study to Evaluate the Efficacy and Safety of SRK-015 in Patients With Later-Onset Spinal Muscular Atrophy (TOPAZ)Status: Completed, Estimated PCD: 2021-01-19
Product
SRK-015Clinical trial
Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients With Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam TherapyStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Product
PlaceboProduct
Apitegromab